We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving the combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitorLazcluze (lazertinib) for use in certain patients with non-small cell lung cancer (NSCLC).
The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. The FDA approved this combination in August for a similar indication.
This recommendation is based on data from the phase III MARIPOSA study, which evaluated the Rybrevant-Lazcluze combo against AstraZeneca’s (AZN - Free Report) blockbuster oncology drug Tagrisso in patients with the above indication.
Data from the MARIPOSA study showed that treatment with the JNJ combination therapy reduced the risk of disease progression or death by 30% compared with AZN’s Tagrisso. Patients who took the combo achieved a median duration of response (mDOR) that was nine months longer than those treated with the AstraZeneca drug.
JNJ Stock Performance
Year to date, J&J’s shares have moved down 1.8% against the industry’s 3.3% growth.
Image Source: Zacks Investment Research
Recent Developments Related to JNJ's Rybrevant
In August, the European Commission approved the combination of Rybrevant and standard-of-care chemotherapy (carboplatin and pemetrexed) for treating adult patients with advanced NSCLC with EGFR ex19del or L858R mutations after failure of prior therapy, including an EGFR-TKI. This combination received the FDA’s approval for use in a similar indication in September.
Rybrevant also received approval for a third indication in the United States. In March, the FDA approved the combination of Rybrevant and chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The combination is also approved for a similar indication in the EU.
Through these approvals, the J&J drug intends to take on AstraZeneca’s Tagrisso, which is the current standard of care for EGFR-mutated NSCLC.
In June, J&J submitted a regulatory filing with the FDA seeking approval for a subcutaneous formulation of Rybrevant for all currently approved or submitted indications of the drug. Per management, the FDA granted this filing a priority designation in August.
Apart from NSCLC, J&J is also evaluating Rybrevant in other cancer indications. In September, management reported new data from the phase Ib/II OrigAMI-1 study, which evaluated the combination of Rybrevant plus chemotherapy in certain patients with metastatic colorectal cancer. Patients who received the combo therapy achieved an overall response rate of 49% and a disease control rate of 88%.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 30.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.38. Estimates for 2025 loss per share have narrowed from $1.54 to $1.16. Year to date, shares of Spero Therapeutics have lost 19.7%.
Spero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Johnson & Johnson (JNJ - Free Report) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving the combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitorLazcluze (lazertinib) for use in certain patients with non-small cell lung cancer (NSCLC).
The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. The FDA approved this combination in August for a similar indication.
This recommendation is based on data from the phase III MARIPOSA study, which evaluated the Rybrevant-Lazcluze combo against AstraZeneca’s (AZN - Free Report) blockbuster oncology drug Tagrisso in patients with the above indication.
Data from the MARIPOSA study showed that treatment with the JNJ combination therapy reduced the risk of disease progression or death by 30% compared with AZN’s Tagrisso. Patients who took the combo achieved a median duration of response (mDOR) that was nine months longer than those treated with the AstraZeneca drug.
JNJ Stock Performance
Year to date, J&J’s shares have moved down 1.8% against the industry’s 3.3% growth.
Image Source: Zacks Investment Research
Recent Developments Related to JNJ's Rybrevant
In August, the European Commission approved the combination of Rybrevant and standard-of-care chemotherapy (carboplatin and pemetrexed) for treating adult patients with advanced NSCLC with EGFR ex19del or L858R mutations after failure of prior therapy, including an EGFR-TKI. This combination received the FDA’s approval for use in a similar indication in September.
Rybrevant also received approval for a third indication in the United States. In March, the FDA approved the combination of Rybrevant and chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The combination is also approved for a similar indication in the EU.
Through these approvals, the J&J drug intends to take on AstraZeneca’s Tagrisso, which is the current standard of care for EGFR-mutated NSCLC.
In June, J&J submitted a regulatory filing with the FDA seeking approval for a subcutaneous formulation of Rybrevant for all currently approved or submitted indications of the drug. Per management, the FDA granted this filing a priority designation in August.
Apart from NSCLC, J&J is also evaluating Rybrevant in other cancer indications. In September, management reported new data from the phase Ib/II OrigAMI-1 study, which evaluated the combination of Rybrevant plus chemotherapy in certain patients with metastatic colorectal cancer. Patients who received the combo therapy achieved an overall response rate of 49% and a disease control rate of 88%.
JNJ’s Zacks Rank
J&J currently carries a Zacks Rank #3 (Hold).
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) and Spero Therapeutics (SPRO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 30.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.38. Estimates for 2025 loss per share have narrowed from $1.54 to $1.16. Year to date, shares of Spero Therapeutics have lost 19.7%.
Spero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.